Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised
| Image |  |
|---|---|
| Description | scientific article published on 16 March 2018 |
| Author/s |
author: Rui-Hua Xu Sae-Won Han |
| Publication date | March 16, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |